Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 11/20 | 0.53 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.36 |
| ▸ | BIRC3 | Q13489 | 1/20 | 0.36 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16930725 | 0.92 | XIAP (0.51) | XIAPCTSL | |
| SCHEMBL15569087 | 0.85 | XIAP (0.73) | XIAP | |
| SCHEMBL15569752 | 0.82 | GHSR (0.42) | XIAPTRPM8ACE | |
| SCHEMBL15568295 | 0.79 | XIAP (0.53) | XIAP | |
| SCHEMBL16930757 | 0.78 | XIAP (0.49) | XIAP | |
| SCHEMBL15569337 | 0.78 | XIAP (0.50) | XIAPACE | |
| SCHEMBL16930723 | 0.76 | XIAP (0.72) | XIAP | |
| SCHEMBL15569092 | 0.74 | XIAP (0.71) | XIAP | |
| SCHEMBL16930770 | 0.74 | XIAP (0.37) | XIAPACE | |
| SCHEMBL16930745 | 0.74 | XIAP (0.37) | XIAPACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422332-B2 | Azaheterocycles as BIR2 and/or BIR3 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20150210739-A1 | AZAHETEROCYCLES AS BIR2 AND/OR BIR3 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2015-07-30 | — | — | US | disclosed |
| EP-2885275-A1 | AZAHETEROCYCLES AS BIR2 AND/OR BIR3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2015-06-24 | — | — | EP | disclosed |
| WO-2014026882-A1 | AZAHETEROCYCLES AS BIR2 AND/OR BIR3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210739-A1 | AZAHETEROCYCLES AS BIR2 AND/OR BIR3 INHIBITORS | BIRC3, BIRC5, BIRC2 | XIAP 4/4885TRPM8 4794/4885F2RL1 3452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.